Loading the content... Loading depends on your connection speed!

Shopping Cart - $0.00

Bladder Cancer Market Global Briefing 2017

Bladder Cancer Market Global Briefing 2017

From $1,000.00

Including: Chemotherapy, Radiation Therapy, Immunotherapy Segments.
Covering: Astra Zeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, F. Hoffmann-La Roche


Clear selection
SKU: 2261. Category: .
Description

Bladder Cancer Market Global Briefing 2017 from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global bladder cancer market.

Description

The Bladder Cancer Market Global Briefing Report from The Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The bladder cancer market is one of the segments in the oncology drugs market, within the pharmaceutical drugs market.

The market characteristics section of the report defines and explains the market.

The market size section gives the bladder cancer market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the bladder cancer market and suggests approaches.

Reasons to Purchase

• Get up to date information available on the bladder cancer market globally.
• Identify growth segments and opportunities.
• Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
• Develop strategies based on likely future developments.
• Gain a global perspective on the development of the market.
• Report will be updated with the latest data and delivered to you within 2-3 working days of order.

Scope

Markets Covered: Chemotherapy, Radiation Therapy, Immunotherapy segments.

Companies Mentioned: Astra Zeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, F. Hoffmann-La Roche.

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Market value in $ billions.

Data segmentations: Regional breakdowns, market share of competitors, key sub segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Related Reports:
Lung cancer Market Global Briefing 2017
Pancreatic cancer Market Global Briefing 2017
Breast cancer Market Global Briefing 2017
Prostate cancer Market Global Briefing 2017
Ovarian cancer Market Global Briefing 2017
Gastric Cancer Market Global Briefing 2017
Non-Small Cell Lung Cancer Market Global Briefing 2017
Brain Tumor Market Global Briefing 2017
Colorectal Cancer Market Global Briefing 2017
Thyroid cancer Market Global Briefing 2017
Kidney Cancer Market Global Briefing 2017
Skin cancer Market Global Briefing 2017
Cervical Cancer Market Global Briefing 2017
Blood cancer Market Global Briefing 2017

Table Of Contents
Table Of Contents

1. Introduction
2. Bladder Cancer Market Characteristics
3. Bladder Cancer Market Historic Growth
• Drivers Of The Market
• Restraints On The Market
4. Bladder Cancer Market Forecast Growth
• Drivers Of The Market
• Restraints On The Market
5. Bladder Cancer Market Geography Split
6. Bladder Cancer Market As A Proportion of Oncology Drugs Market, 2016, By Region
7. Bladder Cancer Market As A Proportion of Oncology Drugs Market, 2016, By Country
8. Bladder Cancer Market Segmentation
9. Bladder Cancer Competitive Landscape
Astra Zeneca
Bristol-Myers Squibb
Celgene
Eli Lilly
F. Hoffmann-La Roche
10. Key Mergers And Acquisitions In The Bladder Cancer Market
11. Bladder Cancer Market Trends And Strategies
Appendix
NAICS Definitions of Industry Covered In This Report
Research Methodology
Methodology
Data
Market Numbers
Competitor Market Share Data
Analysis
Verification Through Expert Interviews
Referencing
Note on Currency Conversions
Abbreviations
Currencies
Research Inquiries
The Business Research Company

List Of Tables
Table 1: Global Bladder Cancer Market Historic Market Size, 2012 – 2016, $ Billion
Table 2: Global Bladder Cancer Market Forecast Market Size, 2016 – 2020, $ Billion
Table 3: Global Bladder Cancer Market, Split By Region, 2016, $ Billion
Table 4: Bladder Cancer Market As A Proportion of Oncology Drugs Market, 2016, By Region
Table 5: Bladder Cancer Market As A Proportion of Oncology Drugs Market, 2016, By Country
Table 6: Global Bladder Cancer Market, Key Competitor Shares, 2016, Percentage (%)
Table 7: Global Bladder Cancer Market, Split By Segments, 2016, $ Billion

List Of Figures
Figure 1: Global Bladder Cancer Market Historic Market Size, 2012 – 2016, $ Billion
Figure 2: Global Bladder Cancer Market Forecast Market Size, 2016 – 2020, $ Billion
Figure 3: Global Bladder Cancer Market, Split By Region, 2016, $ Billion
Figure 4: Bladder Cancer Market As A Proportion of Oncology Drugs Market, 2016, By Region
Figure 5: Bladder Cancer Market As A Proportion of Oncology Drugs Market, 2020, By Country
Figure 6: Global Bladder Cancer Market, Key Competitor Shares, 2016, Percentage (%)
Figure 7: Global Bladder Cancer Market, Split By Segments, 2016, $ Billion
Executive Summary
The bladder cancer drugs market cover drugs that treat cancer that affect tissues of the urinary bladder. These conditions include urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. Based on treatment therapy type, the market is segmented into chemotherapy, radiation therapy, immunotherapy segments. Some of the major bladder cancer drugs include Thiotepa, Tecentriq (Atezolizumab), Platinol-AQ (Cisplatin), Platinol (Cisplatin), Pembrolizumab, Opdivo (Nivolumab), Keytruda (Pembrolizumab), Imfinzi (Durvalumab), Doxorubicin Hydrochloride, Cisplatin, Bavencio (Avelumab), and Atezolizumab.

The global bladder cancer market was estimated to be around $0.28 billion as of 2016. The global bladder cancer made up around 0.24% of the overall oncology drugs market in 2016. The bladder cancer market was the fourteenth largest market in the global oncology drugs market in 2016.

Combination Drugs For Bladder Cancer
Development of combination drugs for the treatment of bladder cancer is an emerging trend in this market. For instance, GEMCITABINE-CISPLATIN is a combination drug is used in chemotherapy for the treatment of biliary tract cancer, bladder cancer, cervical cancer, malignant mesothelioma, non-small cell lung cancer (NSCLC), ovarian cancer, and pancreatic cancer. PLATINOL (cisplatin) is manufactured by Bristol-Myers Squibb and GEMCITABINE is manufactured by Eli Lilly and Company. In 2011, Bristol-Myer Squibb and Eli Lilly and Company collaborated to for a combination drug of GEMCITABINE-CISPLATIN for the treatment of different types of cancer including bladder cancer.

Product Approval
Product approvals from regulatory bodies such as FDA in the US and EMA in Europe is one of the major trend in this market. For instance, in May 2017, AstraZeneca received FDA approval for its immunotherapy drug durvalumab as a treatment for bladder cancer. Through this approval, AstraZeneca focuses to market this drug in the US market and stregthen its position in bladder cancer drugs market in the US.
Get Customized Report
Please fill in your details. Our team will get back to you